Hims & Hers Health, Inc. (NYSE:HIMS) Shares Bought by Strategic Wealth Partners Ltd.

Strategic Wealth Partners Ltd. grew its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 57.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 109,199 shares of the company’s stock after acquiring an additional 39,896 shares during the quarter. Strategic Wealth Partners Ltd. owned about 0.05% of Hims & Hers Health worth $2,011,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its holdings in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after acquiring an additional 1,603 shares during the period. Quest Partners LLC raised its stake in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares in the last quarter. Van ECK Associates Corp bought a new stake in shares of Hims & Hers Health during the second quarter valued at about $111,000. Amalgamated Bank raised its stake in shares of Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after purchasing an additional 2,354 shares in the last quarter. Finally, Daiwa Securities Group Inc. bought a new stake in shares of Hims & Hers Health during the second quarter valued at about $142,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $18.75 on Wednesday. The stock has a market cap of $4.03 billion, a price-to-earnings ratio of -1,875.00 and a beta of 1.06. The business has a 50 day simple moving average of $16.45 and a 200 day simple moving average of $17.33. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $25.74.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The firm had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. During the same period in the previous year, the company earned ($0.03) EPS. The company’s revenue for the quarter was up 51.8% on a year-over-year basis. On average, analysts predict that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Soleil Boughton sold 2,335 shares of the stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $20.29, for a total transaction of $47,377.15. Following the completion of the transaction, the insider now directly owns 166,809 shares in the company, valued at $3,384,554.61. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of Hims & Hers Health stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $22.00, for a total value of $45,188.00. Following the completion of the transaction, the insider now owns 185,326 shares in the company, valued at approximately $4,077,172. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 2,335 shares of Hims & Hers Health stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $20.29, for a total value of $47,377.15. Following the completion of the transaction, the insider now owns 166,809 shares of the company’s stock, valued at approximately $3,384,554.61. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 573,618 shares of company stock worth $9,329,808 over the last 90 days. Corporate insiders own 17.71% of the company’s stock.

Analyst Ratings Changes

HIMS has been the topic of a number of recent analyst reports. Bank of America cut their price objective on shares of Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, September 13th. Jefferies Financial Group lifted their price objective on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, June 27th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Piper Sandler reiterated a “neutral” rating and issued a $18.00 price target on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Finally, Imperial Capital cut shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Moderate Buy” and an average price target of $19.86.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.